Structural basis for recognition of CD20 by therapeutic antibody Rituximab - Wikidata - awgldk - TriplyDB

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

http://www.wikidata.org/entity/Q27644280

about

A differential cell capture assay for evaluating antibody interactions with cell surface targets.The protein-protein interface evolution acts in a similar way to antibody affinity maturation.Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma.Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential.Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.Targeted drug delivery for cancer therapy: the other side of antibodies.Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.Assessment of physicochemical properties of rituximab related to its immunomodulatory activity.Rituximab-induced early and late signaling have opposite effects on dexamethasone-induced apoptosis in human follicular lymphoma cells.Immunological evaluation of predicted linear B-cell epitopes of human CD20 antigen.Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.Real time analysis of binding between Rituximab (anti-CD20 antibody) and B lymphoma cells Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab.Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q33533684-D66B96A3-08E7-494A-8D33-1C1DDD810253 Q33662167-35A76C13-7F34-4026-B35E-1BF2BCFAA274 Q33798060-DA301702-780B-4C5A-B264-6FCFC2F0C3FF Q35928383-F9F9066F-259B-415A-882D-B3E0ACD6B8D0 Q36940760-737F61B9-1A5D-41D0-BD75-77FD33769EC0 Q37012630-93A24C9B-1DA8-4AA9-8D2D-36237C423D7F Q37112898-1B46CF31-A89E-4C59-B56F-965C6B19E365 Q37212371-2162E558-A060-42DA-858A-60A90619DD0E Q37676785-13837A1B-0B13-4450-8C74-3130E43F7E9B Q38058816-A5D059DE-C60F-4EBB-87BA-D34EADFBA686 Q38406177-A3EFAA5E-C3F1-49DE-B460-C24199F70D76 Q38665518-86CF353F-BE38-48EB-8622-D1DAC8367677 Q38875063-A6C486E0-3107-4D60-820B-AC30A2B4BFEF Q38922646-12630601-8012-45B0-A24F-769E15A6518C Q39166301-1121122E-1B47-41EA-852E-9E245D1A0DD2 Q41966195-EE604F84-6A3E-40EC-B503-0DA2FE2BC291 Q42076420-835653E6-4A27-4E70-8DAD-25EC564EE4DC Q47141959-D0562B73-F459-4639-A63E-7B78A3FD6359 Q49592680-7F69253D-15FE-4049-823E-8DDC2258E243 Q50098437-F663E08A-B542-4C54-AE83-8215AD0077BD Q55283747-D8DC047E-72D5-4995-8C6A-EDEF0CCC9964

P2860

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

http://www.wikidata.org/entity/Q27644280

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@ast

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@en

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@nl

type

label

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@ast

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@en

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@nl

prefLabel

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@ast

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@en

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@nl

P1433

Q27644280-202E9EEF-67BF-4677-9252-7D51740AD7D2

P1476

Q27644280-1834A787-F7A5-4F56-B876-AE9E83D954DF

P2093

Q27644280-29E1D077-AC0A-44ED-8568-CDD8D63FA590

Q27644280-3F0829F3-3465-47A9-881A-2F20EBF0B840

Q27644280-502E6874-0D90-45BB-842A-1E544170E825

Q27644280-80D84024-90F7-416A-A1BB-89695D44FE02

Q27644280-967DB587-6458-400A-B821-53F146F2C5C2

Q27644280-9E433AF5-0191-4916-A40E-2942348325DA

Q27644280-C002D34D-2212-434A-8BFA-E7927DB80DB5

Q27644280-FE315986-73DB-4A72-80BB-B1B2B3AAB5AC

P2860

Q27644280-1583C340-455B-4C33-8FE3-80A8D48635C2

Q27644280-20C1B1E5-E621-42A4-AAB5-ECF4FE2A3D94

Q27644280-37C84CA4-6513-4E73-8353-1E42DD2C9475

Q27644280-3E501941-5F58-486E-9755-0B7B93E9D4DC

Q27644280-3EC84CB1-65E1-4708-943D-B3835A536AB6

Q27644280-588DD96F-A0DE-414A-A901-3E3C893F0300

Q27644280-63C000A0-31E9-410C-B5F5-95074C517FAA

Q27644280-68D4CE48-302C-4151-82E3-02B039B02EA2

Q27644280-6CB6146A-0EAA-4DCA-AB27-DE5225B92400

Q27644280-77AEB845-4469-4ACC-ACD5-4C6C171F588E

P304

Q27644280-46E62A6A-07DB-4360-A68D-8451A2C24AF9

P31

Q27644280-D6FCDB74-5A57-4882-9CC8-B02140363553

P356

Q27644280-86F4637C-1A1E-4E26-BC1D-3D0E50FD6E18

P407

Q27644280-2D23C7FA-43C3-4F34-BAC7-FAA051483E25

P433

Q27644280-7D162A41-8725-499C-BB46-EF3329F1C35B

P478

Q27644280-6B75BEBB-4000-4A8E-A869-15503B131833

P50

Q27644280-0723920F-C673-4120-BFDD-01723ED26A98

P577

Q27644280-7CA21AF9-C246-4E42-B7CB-3A2647663DC1

P698

Q27644280-E73B1858-7501-4962-AD54-ACE97E1F2348

P921

Q27644280-6A862EBC-E6A9-429D-960E-4A9ACEADE335

P356

P1433

Journal of Biological Chemistry

P1476

Structural basis for recognition of CD20 by therapeutic antibody Rituximab

@en

P2093

Baozhen Peng

http://www.w3.org/2001/XMLSchema#string

Chen Zhong

http://www.w3.org/2001/XMLSchema#string

Hao Wang

http://www.w3.org/2001/XMLSchema#string

Jiamu Du

http://www.w3.org/2001/XMLSchema#string

Jianping Ding

http://www.w3.org/2001/XMLSchema#string

Meilan Zhang

http://www.w3.org/2001/XMLSchema#string

Sheng Huo

http://www.w3.org/2001/XMLSchema#string

Yajun Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

Metagrowth: a new resource for the building of metabolic hypotheses in microbiology

Improved methods for building protein models in electron density maps and the location of errors in these models

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

Processing of X-ray diffraction data collected in oscillation mode

VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs

Likelihood-enhanced fast translation functions

Shape complementarity at protein/protein interfaces

The CCP4 suite: programs for protein crystallography

Standard conformations for the canonical structures of immunoglobulins

P304

15073-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M701654200

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

282

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17395584

http://www.w3.org/2001/XMLSchema#string

P921